ReviewCancers2020
Non-Conventional Treatments for Conventional Chondrosarcoma.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- The Role of AXL Signaling and MutantCancers · 2026Review
- Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Genetics and Molecular Pathogenesis of the Chondrosarcoma: A Review of the Literature.Current issues in molecular biology · 2024Review
- Radiosensitizing Effect of PARP Inhibition on Chondrosarcoma and Chondrocyte Cells Is Dependent on Radiation LET.Biomolecules · 2024Article
- Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases.Oncology letters · 2024Article
- The Landscape of microRNAs in Bone Tumor: A Comprehensive Review in Recent Studies.MicroRNA (Shariqah, United Arab Emirates) · 2024Review
- Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities.Molecules and cells · 2023Review
- IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.BMC cancer · 2023Article
- Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions.Cancers · 2023Review
- EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression.eLife · 2023Article
- Anti-tumor effects of deubiquitinating enzyme inhibitor PR-619 in human chondrosarcoma through reduced cell proliferation and endoplasmic reticulum stress-related apoptosis.American journal of cancer research · 2023Article
- Article
- Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives.Cancers · 2022Review
- Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.International journal of molecular sciences · 2022Review
- PLCD1-Induced DNA Damage Inhibits the Tumor Growth via Downregulating CDKs in Chondrosarcoma.Journal of oncology · 2022Article
- The basic characteristics of extracellular vesicles and their potential application in bone sarcomas.Journal of nanobiotechnology · 2021Review
- The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis.Cancers · 2021Review
- Review
- Bone and Soft Tissue Tumors: New Treatment Approaches.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Chondrosarcomas are the most common malignant tumors of the cartilage, are seen predominantly in adults, and have varied clinical behavior. The majority of them affect the medullary canal of long bones and pelvic bones. The prognosis of chondrosarcoma is closely related to histological grading; however, the grading is subject to interobserver variability. Conventional chondrosarcomas are overall considered to be chemotherapy- and radiation-resistant, resulting in limited treatment options. The majority of advanced conventional chondrosarcomas are treated with chemotherapy without any survival benefit. Recent studies have evaluated molecular genetic findings which have improved the understanding of chondrosarcoma biology. Newer therapeutic targets are desperately needed. In this review article, we explore ongoing clinical trials evaluating novel ways of treating advanced conventional chondrosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.